Skip to main content

Advertisement

Log in

Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Background Early change in local intracoronary hemostasis following drug-eluting (DES) and bare metal stent (BMS) implantation has never been assessed in stable angina patients. Methods Markers of local platelet activation (soluble glycoprotein V [sGPV] and P-Selectin [CD62P]), coagulation activation (tissue factor [TF], prothrombin fragments 1 + 2 [F1 + 2] and activated factor VII [FVIIa]) and fibrinolysis markers (D-dimers [DD], fibrinogen [FIB], tissue plasminogen activator [t-PA], and plasminogen activator inhibitor type-1 complexes [PAI-1]) were determined in 20 patients with stable angina who underwent percutaneous coronary intervention (PCI). All patients were pretreated with clopidogrel, aspirin, and enoxaparin. Systematic balloon predilation was performed before DES (9 patients) and BMS (11 patients) implantation. All blood samples were drawn 10–20 mm distal to the lesion site. Results No significant changes in levels of platelet activation markers occurred during PCI. There was a transient significant increase in TF (14%; = 0.004), in F1 + 2 (40%; = 0.001), and FVIIa (31%; = 0.007) following angioplasty. Similarly, a significant 43% increase was observed in DD levels following balloon predilation, associated with an increase of 46%, 60%, and 70% in FIB, t-PA and PAI-1 levels, respectively (all P < 0.0001). All these markers returned to baseline values after stent implantation. No difference was observed between DES and BMS. Conclusions Early changes in local hemostasis activation following PCI, were related to balloon predilation. Neither DES nor BMS increased markers of platelet activation, coagulation, or fibrinolysis, under dual antiplatelet and anticoagulant pretreatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chieffo A, Bonizzoni E, Orlic D, Stankovic G, Rogacka R, Airoldi F et al (2004) Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 109:2732–2736. doi:10.1161/01.CIR.0000131890.83839.5B

    Article  PubMed  CAS  Google Scholar 

  2. Alfonso F, Suarez A, Angiolillo DJ, Sabate M, Escaned J, Moreno R et al (2004) Findings of intravascular ultrasound during acute stent thrombosis. Heart 90:1455–1459. doi:10.1136/hrt.2003.026047

    Article  PubMed  CAS  Google Scholar 

  3. Scheller B, Hennen B, Pohl A, Schieffer H, Markwirth T (2001) Acute and subacute stent occlusion; risk-reduction by ionic contrast media. Eur Heart J 5:385–391. doi:10.1053/euhj.2000.2319

    Article  Google Scholar 

  4. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al (2001) Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103:1967–1971

    PubMed  CAS  Google Scholar 

  5. Honda Y, Fitzgerald PJ (2003) Stent thrombosis. An issue revisited in a changing world. Circulation 108:2–5. doi:10.1161/01.CIR.0000075929.79964.D8

    Article  PubMed  Google Scholar 

  6. Nordmann AJ, Briel M, Bucher HC (2006) Mortality in randomized controlled trials comparing drug-eluting versus bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27:2784–2814. doi:10.1093/eurheartj/ehl282

    Article  PubMed  CAS  Google Scholar 

  7. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130. doi:10.1001/jama.293.17.2126

    Article  PubMed  CAS  Google Scholar 

  8. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678. doi:10.1016/S0140-6736(07)60314-6

    Article  PubMed  CAS  Google Scholar 

  9. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS et al (2004) Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109:1930–1932. doi:10.1161/01.CIR.0000127105.99982.21

    Article  PubMed  Google Scholar 

  10. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ (2004) A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364:583–591. doi:10.1016/S0140-6736(04)16850-5

    Article  PubMed  CAS  Google Scholar 

  11. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al (2004) TAXUS-IV investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947. doi:10.1161/01.CIR.0000127110.49192.72

    Article  PubMed  CAS  Google Scholar 

  12. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M et al (2005) Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45:954–959. doi:10.1016/j.jacc.2004.11.065

    Article  PubMed  CAS  Google Scholar 

  13. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL (2005) What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 45:941–946. doi:10.1016/j.jacc.2004.11.064

    Article  PubMed  Google Scholar 

  14. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL (2005) Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 95:1469–1472. doi:10.1016/j.amjcard.2005.02.015

    Article  PubMed  CAS  Google Scholar 

  15. Gyöngyösi M, Strehblow C, Sperker W, Hevesi A, Garamvölgyi R, Petrási Z et al (2006) Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 h. Thromb Haemost 96:202–209

    PubMed  Google Scholar 

  16. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E (1998) Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 13:3153–3159. doi:10.1093/ndt/13.12.3153

    Article  PubMed  CAS  Google Scholar 

  17. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115:1051–1058. doi:10.1161/CIRCULATIONAHA.106.675934

    Article  PubMed  Google Scholar 

  18. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH et al (1994) Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 15:1484–1491

    Article  Google Scholar 

  19. Eichinger S, Wolz M, Nieszpaur-Los M, Schneider B, Lechner K, Eichler HG et al (1994) Effects of a low molecular weight heparin (Fragmin) and of untractionated heparin on coagulation activation at the site of plug formation in vivo. Thromb Haemost 72:831–835

    PubMed  CAS  Google Scholar 

  20. Weltermann A, Wolzt M, Petersmann K, Czerni C, Graselli U, Lechner K et al (1999) Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 19:1757–1760

    PubMed  CAS  Google Scholar 

  21. Wendling D, Racadot E (2006) Serum tissue factor levels correlate with inflammation in ankylosing spondylitis. Joint Bone Spine 73:403–405. doi:10.1016/j.jbspin.2006.01.018

    Article  PubMed  CAS  Google Scholar 

  22. Inoue T, Hoshi K, Fujito T, Sakai Y, Morooka S, Sohma R (1996) Early detection of platelet activation after coronary angioplasty. Coron Artery Dis 7:529–534. doi:10.1097/00019501-199607000-00007

    Article  PubMed  CAS  Google Scholar 

  23. Korovesis S, Fredericks S, Holt D, Toutouzas P, Kaski JC, Webb-Peploe MM et al (2000) Release of platelet activation markers during coronary angioplasty. Coron Artery Dis 11:391–398. doi:10.1097/00019501-200007000-00003

    Article  PubMed  CAS  Google Scholar 

  24. Borries M, Heins M, Fischer Y, Stiegler H, Peters A, Reinauer H et al (1999) Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. J Am Coll Cardiol 34:486–493. doi:10.1016/S0735-1097(99)00229-6

    Article  PubMed  CAS  Google Scholar 

  25. Shammas NW, Cunningham MJ, Pomerantz RM, Francis CW (1994) Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost 72:672–675

    PubMed  CAS  Google Scholar 

  26. Philipp R, Grech ED (2003) Interventional pharmacotherapy. BMJ 327:43–46. doi:10.1136/bmj.327.7405.43

    Article  PubMed  CAS  Google Scholar 

  27. Agraou B, Corseaux D, McFadden EP, Bauters A, Cosson A, Jude B (1997) Effects of coronary angioplasty on monocyte tissue factor response in patients with stable or unstable angina. Thromb Res 88:237–243. doi:10.1016/S0049-3848(97)00234-X

    Article  PubMed  CAS  Google Scholar 

  28. Katritsis DG, Korovesis S, Giazitzoglou E, Theodorou S, Kourlaba G, Panaqiotakos D et al (2006) Direct versus predilatation drug-eluting stenting: a randomized clinical trial. J Invasive Cardiol 18:475–479

    PubMed  Google Scholar 

  29. Mizuno O, Ikeda U, Hojo Y, Fujikawa H, Katsuki T, Shimada K (2001) Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty. Cardiology 95:84–89. doi:10.1159/000047351

    Article  PubMed  CAS  Google Scholar 

  30. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A (1997) Postangioplasty restenosis platelet activation and the coagulation—fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133:387–392. doi:10.1016/S0002-8703(97)70178-9

    Article  PubMed  CAS  Google Scholar 

  31. Muldowney JA 3rd, Stringham JR, Levy SE, Gleaves LA, Eren M, Piana RN et al (2007) Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 27:400–406. doi:10.1161/01.ATV.0000254677.12861.b8

    Article  PubMed  CAS  Google Scholar 

  32. Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F et al (1992) A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 67:209–213

    PubMed  CAS  Google Scholar 

  33. Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M et al (2001) Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 104:181–186. doi:10.1016/S0049-3848(01)00360-7

    Article  PubMed  CAS  Google Scholar 

  34. Maresca G, Di Blasio A, Marchioli R, Di Minno G (1999) Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 19:1368–1377

    PubMed  CAS  Google Scholar 

  35. Lowe GD, Rumley A (1999) Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 82:667–672

    PubMed  CAS  Google Scholar 

  36. Sakharov DV, Kalachev LV, Rijken DC (2002) Numerical simulation of local pharmacokinetics of a drug after intravascular delivery with an eluting stent. J Drug Target 10:507–513. doi:10.1080/1061186021000038382

    Article  PubMed  CAS  Google Scholar 

  37. Kereiakes DJ, Choo JK, Young JJ, Broderick TM (2004) Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 5:9–15. doi:10.1016/j.carrad.2004.04.002

    Article  PubMed  Google Scholar 

  38. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF et al (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112:2002–2011. doi:10.1161/CIRCULATIONAHA.105.569129

    Article  PubMed  CAS  Google Scholar 

  39. Stahli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M et al (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99:149–155. doi:10.1161/01.RES.0000233379.92010.fd

    Article  PubMed  CAS  Google Scholar 

  40. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN (2000) Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: part I—pathophysiological and pharmacological features. Neurosurgery 46:1344–1359. doi:10.1097/00006123-200006000-00012

    Article  PubMed  CAS  Google Scholar 

  41. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW et al (2006) Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98:352–356. doi:10.1016/j.amjcard.2006.02.039

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nicolas Meneveau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahemuti, A., Meneveau, N., Seronde, MF. et al. Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents. J Thromb Thrombolysis 28, 333–341 (2009). https://doi.org/10.1007/s11239-008-0266-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-008-0266-2

Keywords

Navigation